VERICEL CORPORATION Derivative Liability, Current
VERICEL CORPORATION (VCEL) had Derivative Liability, Current of $0 as of 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2019-02-26
- 2018-12-31: Derivative Liability, Current $0.00.
- 2018-09-30: Derivative Liability, Current $0.00.
- 2018-06-30: Derivative Liability, Current $1.55M.
- 2018-03-31: Derivative Liability, Current $1.92M.
| Period end | Derivative Liability, Current |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-26 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 |
| 2018-06-30 | $1.55M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $1.92M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $1.01M 10-K · filed 2019-02-26 |
| 2017-09-30 | $1.27M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $209.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $650.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $757.00K 10-Q · filed 2017-11-07 |
| 2016-09-30 | $658.00K 10-Q · filed 2016-11-07 |
| 2015-12-31 | $757.00K 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |